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Acceptance criteria for liver allografts are ever more expanding because of a persisting wait-list mortality. Older livers are 
therefore offered and used more frequently for transplantation. This study aims to analyze the use and longterm outcome of 
these transplantations. Data were included on 17,811 first liver transplantations (LTs) and information on livers that were 
reported for allocation but not transplanted from 2000 to 2015 in the Eurotransplant (ET) region. Graft survival was defined 
as the period between transplantation and date of retransplantation or date of recipient death. In the study period, 2394 (13%) 
transplantations were performed with livers ≥70 years old. Graft survival was 74%, 57%, and 41% at 1-, 5-, and 10-year follow-
up, respectively. A history of diabetes mellitus in the donor (hazard ratio [HR], 1.3; P = 0.01) and positive hepatitis C virus 
antibody in the recipient (HR, 1.5; P < 0.001) are specific risk factors for transplantations with livers ≥70 years old. Although 
donor age is associated with a linearly increasing risk of graft loss between 25 and 80 years old, no difference in graft survival 
could be observed when “preferred” recipients were transplanted with a liver <70 or ≥70 years old (HR 1.1; CI 0.92-1.23, 
P = 0.40) or with a donor <40 or ≥70 years old (HR 1.2; CI 0.96-1.37, P = 0.13). Utilization of reported livers ≥70 years old 
increased from 42% in 2000-2003 to 76% in 2013-2015 without a decrease in graft survival (P = 0.45). In conclusion, an 
 important proportion of LTs in the ET region are performed with livers ≥70 years old. The risk of donor age on graft loss 
increases linearly between 25 and 80 years old. Livers ≥70 years old can, however, be transplanted safely in preferred patients 
and are to be used more frequently to further reduce wait-list mortality.
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The number of patients registered for a liver trans-
plantation (LT) in the Eurotransplant (ET) region 
exceeds the number of available liver allografts. In 
2016, 2258 patients were registered for a LT, and 1567 
transplantations were performed. Wait-list mortality 
is therefore a serious issue: Over 500 patients died in 
2016 while waiting and over 1700 patients were still 
on the waiting list at the year’s end.(1) To increase the 
number of transplantations, the acceptance criteria 
for LT have been stretched increasingly in the past 
decade. One of the criteria that is being expanded is 
donor age. As a result, mean donor age has increased 
from 25 years old in 1990 to 55 years old in 2016.(1) 
This development is illustrated by the significant 
increase in donors aged 70 years or older.(2) These 
older livers can increase the number of LT and are 
therefore an important source to help decrease wait-
list mortality.
de BOer et al.
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However, they are likely to negatively affect post-
transplantation outcomes because donor age is a well-
known risk factor.(3) For example, it has been included 
as an important risk factor in several outcome models, 
like the donor risk index (DRI),(4) ET-DRI,(5) and BAR 
score.(6) The latter uses a cutoff for older donors of 40 
years old,(6) whereas the DRI and ET-DRI have donor 
age categorized into 5 age categories. The category with 
the oldest livers comprises all livers from donors of 70 
years and older and is associated with a hazard ratio 
(HR) of 1.65 and 1.62 for the DRI and ET-DRI, respec-
tively.(4,5) Although these risk models use cut-off values 
for donor age, the actual summative effect of donor age 
on posttransplantation outcome is yet unclear, especially 
when transplanting livers from donors ≥70 years.
The demographical transition in Western countries 
with aging populations and promising posttransplanta-
tion results(7-9) indicates that this practice will become 
increasingly more common. The current substantial 
use might therefore just be the onset of a far more 
common one in Europe and the United States.(10) It 
questions whether there are limits to donor age at all 
and urges a thorough analysis of the current practice of 
transplantations with elderly donors.
This study aims to analyze the effect of an increas-
ing donor age on outcomes after LT in the ET region. 
Second, an evaluation of the current and potential use 
of liver allografts from donors of 70 years and older is 
performed.
Patients and Methods
design
All first LTs performed in adult recipients (≥18 years) 
with liver allografts from deceased donors from January 
1, 2000 until December 31, 2015 in the ET region were 
included. Follow-up data were obtained from the ET 
Network Information System and ET Liver Registry 
up to March 2017. Also, data were obtained on the 
reported but nontransplanted liver allografts from do-
nors of 70 years and older within the study period. The 
study protocol was approved by the ET Liver Intestine 
Advisory Committee, and no ethical statement was 
required according to European guidelines and Dutch 
law because data were anonymized and patients were 
not (directly) involved and/or affected.
OUtcOMe MeasUres
Graft survival at 1-, 5-, and 10-year follow-up was 
considered as primary outcome measure. Graft sur-
vival was defined as the period between the date of 
transplantation and date of retransplantation or date 
of recipient death, whichever occurred first (nondeath 
censored graft survival). Patient survival at 1, 5, and 10 
years was considered a secondary outcome and was de-
fined as the time between the date of transplantation 
and the death date. Utilization rate was defined as the 
proportion of liver allografts used for liver-only trans-
plantations in adult recipients divided by the sum of 
livers used for first liver–only transplantations in adult 
recipients and all reported but nontransplanted livers.
preFerred recipients
Preferred and nonpreferred recipients were defined 
according to the criteria as published by Segev et al.(11) 
They identified a group of patients by selecting first time, 
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nonstatus 1 recipients with an age >45 years, body mass 
index (BMI) <35 kg/m2, an indication other than hepa-
tocellular carcinoma (HCC) or hepatitis C virus (HCV), 
and a cold ischemia time (CIT) <8 hours. In our study, 
we only considered recipients with an age >45 years, 
BMI <35 kg/m2, an indication other than HCV, and a 
CIT <8 hours as preferred recipients. Retransplantations 
were not included in this study, and the definition of (the 
equivalent of) status 1 recipients changed over the study 
period. In addition, HCC could not be analyzed because 
the presence of HCC was not registered for the entire 
study period as a separate variable or as a category in the 
etiology of the liver disease variable.
transplant centers
Transplant centers were first categorized by the me-
dian number of LTs with livers ≥70 years old in a low- 
and high-volume group. Subsequently, centers were 
categorized by the median proportion of transplanta-
tions performed with livers ≥70 years old as compared 
with all transplantations performed in that center and 
included in this study. Then, centers were categorized 
according to outcome of transplantations with livers 
≥70 years in “better than expected,” “worse than ex-
pected,” and “as expected” based on the 95% confi-
dence interval (CI).(12)
data analYsis
Clinical characteristics were summarized by median 
and 25% and 75% interquartile range (IQR) or by n 
(%) for continuous and categorical factors, respectively. 
Factors between groups were compared using Kruskal-
Wallis (continuous) and chi-square tests (categorical). 
Missing values were imputed with the median value 
for gamma-glutamyltransferase (GGT; 34 U/L, 2%), 
aspartate aminotransferase (ASAT; 41 U/L, 1%), al-
anine aminotransferase (ALAT; 29 U/L, 1%), and 
bilirubin (9.4 µmol/L, 3%). Missing CITs (37%) were 
imputed based on 3 factors: allocation (local, regional, 
and extraregional), 3 years’ nondeath-censored graft 
survival, and CITs in a 5-fold database by multiple 
imputation using chained equations. Diabetes melli-
tus (DM) in the donor was considered present in case 
of a medical history of DM type 1, 2, and “positive 
but unspecified.” Rescue allocation, cardiac arrest, and 
hypotensive periods in the donor were considered ab-
sent when missing. Donor hepatitis C virus antibody 
(HCVAb), hepatitis B core antibody (HBcAb), and re-
cipient HCVAb were considered negative when missing 
(1%, 1%, and 24%, respectively) or not tested (0%, 2%, 
and 8%, respectively). The ET-DRI(5) was calculated 
for all transplantations, and the simplified recipient risk 
index (sRRI) and donor-to-recipient model (DRM)(13) 
were calculated for all patients with a known Model 
for End-Stage Liver Disease (MELD) score. MELD 
score was only known for recipients that were listed in 
the time period after December 16, 2006 because then 
MELD score was implemented in ET.
statistical analYsis
Posttransplantation outcomes at 10 years were an-
alyzed with Kaplan-Meier analysis and by log-rank 
test. Results were stratified for 4 donor age categories 
(<60, 60-69, 70-79, and ≥80 years). A possible correla-
tion between donor age and laboratory MELD score 
was tested with a Cox regression model. Subsequently, 
factors potentially associated with graft survival were 
analyzed in a multivariate Cox regression model in 
transplantations with livers from donors ≥70 years 
old. The specific effect of donor age was visualized by 
using splines regression when adjusted for donor and 
risk factors (DRM). Then, the effect of donor age on 
outcome was analyzed in preferred and nonpreferred 
recipients. Within both patient categories, outcome 
was stratified by 2 donor age categories: livers from 
donors <70 years old and ≥70 years old and for livers 
from donors <40 and ≥70 years old. Center outcome 
for transplantations with livers ≥70 years old was ac-
cording to volume and proportion of LTs with livers 
≥70 years old in a Kaplan-Meier analysis, and then, ac-
cording to their relative performance on graft survival 
at 5-year follow-up in a funnel-plot analysis. Centers 
with few such transplantations were excluded for this 
analysis (<10 LTs). To analyze the utilization rate, liv-
ers from donors ≥70 years old that were reported to 
ET were compared by transplantation status (yes/no).
A P value of <0.05 was considered statistically sig-
nificant, and all analyses were performed with SPSS, 
version 24.0 (IBM, Armonk, NY) and R, version 3.3.2 
(R Project for Statistical Computing, Vienna, Austria).
Results
stUdY pOpUlatiOn
In the study period, 17,811 first LTs were performed 
in adult recipients within the ET region. Mean 
follow-up period was 6.3 years. Median donor age 
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of all transplanted livers was 51 years old (maximum 
98 years) and increased from 42 to 55 years (Fig. 1). 
Nearly half of all transplanted livers were allocated 
extraregionally (45%) and 23% were allocated in res-
cue allocation. Median ET-DRI was 1.8 (1.5-2.2) 
with donor age included and 1.4 (1.3-1.6) without 
donor age. Recipients had a median age of 54 years, 
and median laboratory MELD score was 16. Other 
demographics on donor, transplantation, and recipient 
characteristics are shown in Tables 1 and 2. Overall 
graft survival was 76%, 63%, and 49% after 1, 5, and 
10 years, respectively, and patient survival was 81%, 
69%, and 55% after 1, 5, and 10 years, respectively.
OUtcOMe BY dOnOr age 
grOUps
Of all transplantations, 15,147 (85%) were performed 
with donors <70 years old and 2014 (11%), 369 (2%), 
and 11 (0.06%) transplantations were performed with 
livers from septuagenarian, octogenarian, and nona-
genarian donors, respectively (Fig. 2; Table 3). The 
percentage of LTs with donors ≥70 years old increased 
significantly throughout the study period (P < 0.001). 
Donor and recipient characteristics per donor age cate-
gory are shown in Table 4. In this table, characteristics 
of transplantations with livers from donors <70 years 
old and >70 years old were compared. Cerebral vas-
cular accident as cause of death was more frequent in 
transplanted livers ≥70 years old, whereas trauma was 
more frequent in younger donors. DM had a higher 
prevalence in livers ≥70 years old (16% versus 5%; 
P < 0.001) in contrast to cardiac arrest (4% versus 13%; 
P < 0.001). Furthermore, CITs were longer in trans-
planted livers <70 years old (8.9 versus 8.7, P < 0.001). 
The ET-DRI—as a measurement of donor quality—
was significantly different in both groups (1.7 versus 
2.4; P < 0.001), but no significant difference was 
shown with the factor donor age set at reference (1.4 
versus 1.4; P = 0.31).
Patients transplanted with a liver ≥70 years old were 
older as compared with recipients of livers from donors 
<70 years old (58 versus 54 years old; P < 0.001). The 
recipients of older livers did also have a lower median 
Fig. 1. Trends in donor age. Median donor age increased from 42 to 55 years old from 2000-2015.
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taBle 1. demographics of all livers Used for First 
liver–Only transplantations in 2000-2015
Value (n = 17,811)
Donor factor
Age, years 51 (40-63)
Height, cm 175 (166-180)
Weight, kg 75 (68-85)
BMI, kg/m2 25 (23-28)
Sex, male 9713 (55)
HCVAb (positive) 138 (1)
HBcAb (positive) 1001 (6)
Cause of death
Anoxia 1421 (8)
Circulational 556 (3)
CNS tumor 104 (1)
CVA/stroke 10,659 (60)
Head trauma 4186 (24)
Other 885 (5)
DCD 744 (4)
Split liver 641 (4)
CT present 1725 (10)
Ultrasound abdomen present 13,316 (75)
Cardiac arrest (yes) 2098 (12)
Hypotensive period (yes) 3131 (18)
Diabetes (yes) 1203 (7)
Latest laboratory values
GGT, U/L 34 (18-76)
ASAT, U/L 41 (25-72)
ALAT, U/L 29 (17-55)
Bilirubin, umol/L 9.4 (6.0-14.7)
Donor country
Germany 10,350 (58)
Hungary* 240 (1)
The Netherlands 1593 (9)
Belgium 2694 (15)
Croatia† 803 (5)
Slovenia‡ 334 (2)
Austria 1751 (10)
Luxemburg 46 (<1)
Transplant factor
Allocation
Local 5121 (29)
Regional 4614 (26)
Extraregional 8076 (45)
Rescue allocation (yes) 4011 (23)
CIT, hours 8.87 (7.00-10.85)
ET-DRI 1.8 (1.5-2.2)
ET-DRI without age 1.4 (1.3-1.6)
NOTE: Data are given as n (%) or median (IQR).
*Joined ET in May 2013.
†Joined ET in May 2007.
‡Joined ET in January 2000.
taBle 2. demographics of all recipients receiving a 
First liver–Only transplantation in 2000-2015
Recipient factor Value (n = 17,811)
Age, years 54 (47-61)
Height, cm 173 (167-180)
Weight, kg 77 (67-88)
BMI, kg/m2 25 (23-29)
Laboratory MELD 16 (11-27)
Match MELD* 23 (16-31)
Sex, male 11,796 (66)
HCVAb (positive) 3474 (19)
Primary disease on waiting list
Metabolic 612 (3)
Acute 1496 (8)
Cholestatic 2018 (11)
Alcoholic 4102 (23)
Malignant 3138 (18)
HBV 603 (3)
HCV 1516 (9)
Other cirrhosis 3334 (19)
Other/unknown 992 (6)
Laboratory MELD category
<15 5059 (28)
15-25 3688 (21)
26-34 1851 (10)
35+ 1698 (10)
Missing 5515 (31)
Country of transplantation
Germany 10,651 (60)
Hungary† 170 (1)
The Netherlands 1434 (8)
Belgium 2756 (15)
Croatia‡ 787 (4)
Slovenia§ 243 (1)
Austria 1770 (10)
Luxemburg 0 (0)
sRRI|| 1.9 (1.6-2.3)
DRM without donor age || 2.5 (2.0-3.0)
DRM with donor age|| 2.9 (2.3-3.6)
NOTE: Data are given as n (%) or median (IQR).
*Match MELD values are either the exceptional or laboratory 
MELD score used for matching.
†Joined ET in May 2013.
‡Joined ET in May 2007.
§Joined ET in January 2000.
||Calculated for patients listed after MELD implementation, 
December 2006 (n = 12,296).
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laboratory MELD score (16 versus 17; P < 0.001). 
Another difference was observed in primary diagnosis. 
Recipients of liver allografts ≥70 years old more often 
had a malignant disease (24% versus 17%) and alco-
holic liver cirrhosis (30% versus 22%).
When analyzing graft survival, significant dif-
ferences were observed across donor age categories 
(<70, 70-79, and ≥80 years) at 5-year (P ≤ 0.001) and 
10-year follow-up (P ≤ 0.001; Fig. 2A). No difference 
in 1-year graft survival could be detected (P = 0.09). 
Similar differences were observed for patient survival: 
no difference at 1-year follow-up (P = 0.19) but sig-
nificant differences at 5-year (P ≤ 0.001) and 10-year 
follow-up (P ≤ 0.001; Fig. 2B). A potential change in 
outcome throughout the study period was evaluated 
for LTs with donors of ≥70 years per year. However, 
no effect of transplant year (P = 0.30) or when grouped 
into 5 transplant periods (P = 0.45) could be detected 
for graft survival at 5-year follow-up (data not shown).
risK FactOrs in 
transplantatiOns WitH 
Older liver allOgraFts
Multivariate analysis in transplantations with liv-
ers from donors ≥70 years old showed the following 
significant risk factors for graft survival at 10-years 
 follow-up: donor age (P = 0.02), a history of DM in the 
donor (P = 0.01), CIT (P = 0.001), rescue allocation 
(P = 0.02), a recipient age of <45 years old (P = 0.01), 
Fig. 2. Kaplan-Meier analysis of survival by donor age category (n = 17,811).
taBle 3. graft and patient survival rates
1 Year 5 Years 10 Years
Graft survival
<70 years (n = 15,147)
Survival 76% 63% 50%
Number of events 3527 4989 5722
Number at risk 10,775 5296 1680
70-79 years (n = 2014)
Survival 75% 58% 43%
Number of events 483 707 782
Number at risk 1358 507 99
≥80 years (n = 380)
Survival 71% 51% 28%
Number of events 103 154 169
Number at risk 238 65 9
P value 0.089 <0.001 <0.001
Patient survival
<70 years (n = 15,147)
Survival 81% 69% 56%
Number of events 2763 4124 4837
Number at risk 11,480 5818 1900
70-79 years (n = 2014)
Survival 80% 64% 48%
Number of events 388 595 673
Number at risk 1436 556 110
≥80 years (n = 380)
Survival 79% 58% 36%
Number of events 76 126 141
Number at risk 262 76 11
P value 0.188 <0.001 <0.001
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taBle 4. characteristics of all transplantations in 2000-2015 per donor age category
<70 Years  
(n = 15,417)
≥70 Years  
(n = 2394) P Value
70-79 Years 
(n = 2014)
80-89 Years 
(n = 369)
≥90 Years  
(n = 11)
Donor factor  
Age, years 49 (38-58) 74 (72-78) <0.001 73 (71- 76) 82 (81-84) 90 (90-94)
Height, cm 175 (168-180) 170 (165-175) <0.001 170 (165-175) 165 (160-174) 160 (160-165)
Weight, kg 75 (68-85) 75 (70-85) <0.001 75 (70-85) 73 (65-80) 63 (60-70)
BMI, kg/m2 25 (23-28) 26 (24-28) <0.001 26 (24-28) 26 (24-28) 24 (22-26)
Sex, male 8649 (56) 1064 (44) <0.001 927 (46) 136 (37) 1 (9)
HCVAb (positive) 131 (1) 7 (<1) 0.004 7 (0) 0 (0) 0 (0)
HBcAb (positive) 800 (5) 201 (8) <0.001 159 (8) 42 (11) 0 (0)
Cause of death <0.001
Anoxia 1317 (9) 104 (4) 90 (4) 14 (4) 0 (0)
Circulational 511 (3) 45 (2) 41 (2) 4 (1) 0 (0)
CNS tumor 102 (1) 2 (<1) 2 (0) 0 (0) 0 (0)
CVA/stroke 8817 (57) 1842 (77) 1555 (77) 278 (75) 9 (82)
Trauma 3843 (25) 343 (14) 273 (14) 68 (18) 2 (18)
Other 827 (5) 58 (2) 53 (3) 5 (1) 0 (0)
DCD 717 (5) 27 (1) <0.001 26 (1) 1 (<1) 0 (0)
Split liver 641 (4) 0 (0) <0.001 0 (0) 0 (0) 0 (0)
Imaging
CT abdomen result present 1501 (10) 224 (9) 0.56 190 (9) 33 (9) 1 (9)
Ultrasound abdomen present 11,200 (73) 2216 (93) <0.001 1770 (88) 336 (91) 10 (91)
Previous medical history
Diabetes 816 (5) 387 (16) <0.001 323 (16) 62 (17) 2 (18)
Cardiac arrest 1998 (13) 100 (4) <0.001 88 (4) 12 (3) 0 (0)
Hypotensive periods 2871 (19) 260 (11) <0.001 216 (11) 44 (12) 0 (0)
Last laboratory values
Last GGT (U/L) 34 (18-80) 30 (17-58) <0.001 31 (17-61) 25 (14-47) 22 (10-36)
Last ASAT (U/L) 42 (25-75) 35 (24-58) <0.001 35 (24-58) 35 (23-54) 39 (30-65)
Last ALAT 30 (18-58) 21 (15-37) <0.001 22 (15-38) 18 (13-30) 25 (20-29)
Last bilirubin 9.4 (5.8-14.1) 10.3 (6.8-15.6) <0.001 10.3 (6.8-15.8) 10.3 
(6.9-15.4)
12.4 (9.0-17.1)
Transplant factor
Allocation <0.001
Local 4382 (28) 739 (31) 633 (31) 100 (27) 6 (55)
Regional 3953 (26) 661 (28) 550 (27) 108 (29) 3 (27)
Extraregional 7082 (46) 994 (42) 831 (41) 161 (44) 2 (18)
Rescue (yes) 3162 (21) 849 (35) <0.001 678 (34) 204 (55) 6 (55)
CIT, hours 8.9 (7.0-10.9) 8.7 (6.8-10.6) <0.001 8.7 (6.9-10.7) 8.2 (6.5-10.4) 7.9 (5.3-11.1)
ET-DRI without donor age 1.4 (1.3-1.6) 1.4 (1.3-1.5) 0.31 1.5 (1.3-1.5) 1.5 (1.3-1.5) 1.4 (1.2-1.5)
ET-DRI 1.7 (1.5-2.0) 2.4 (2.1-2.5) <0.001 2.4 (2.1-2.5) 2.4 (2.1-2.5) 2.2 (1.9-2.5)
Transplantation period <0.001
2000-2003 3287 (21) 109 (5) 96 (5) 13 (4) 0 (0)
2004-2006 2631 (17) 293 (12) 256 (13) 36 (10) 1 (9)
2007-2009 3168 (21) 508 (21) 424 (21) 82 (22) 2 (18)
2010-2012 3218 (21) 798 (33) 662 (33) 133 (36) 3 (27)
2013-2015 3113 (20) 686 (29) 576 (29) 105 (28) 5 (46)
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MELD score category (P < 0.001), and HCVAb 
status of the recipient (P < 0.001; Fig. 3; Table 5). 
Interestingly, recipient age as a continuous variable was 
not associated with inferior graft survival in the mul-
tivariate analysis. When outcome of transplantations 
with livers ≥70 years old was stratified for recipient 
age (<45 years old, n = 217; 45-55 years old, n = 650; 
55-65 years old, n = 1120; >65 years old, n = 407), in-
ferior survival was observed in recipients <45 years old 
with a survival rate of 54% as compared with recipients 
≥45 years old with an overall survival rate of 59% (P 
< 0.001). No differences were observed between the 
age categories in recipients >45 years old (P < 0.69; 
Supporting Fig. 1). No clear cutoff value for laboratory 
MELD score could be identified for transplanting 
livers ≥70 years old (data not shown). The risk of an 
increasing donor age (adjusted for donor and recipient 
risks) is shown in Fig. 3. It shows a stable risk up to a 
<70 Years  
(n = 15,417)
≥70 Years  
(n = 2394) P Value
70-79 Years 
(n = 2014)
80-89 Years 
(n = 369)
≥90 Years  
(n = 11)
Recipient factor
Age, years 54 (46-60) 58 (51-63) <0.001 58 (51-63) 58 (51-63) 58 (51-75)
Height, cm 173 (167-180) 172 (166-178) <0.001 172 (166-178) 172 (165-178) 170 (162-171)
Weight, kg 77 (66-88) 78 (68-89) 0.01 78 (68-89) 75 (66-88) 75 (69-88)
BMI, kg/m2 25 (23-29) 26 (23-29) <0.001 26 (23-29) 26 (23-29) 27 (25-28)
Laboratory MELD 17 (11-28) 16 (11-23) <0.001 16 (11-24) 15 (10-20) 18 (13-25)
Match MELD* 23 (15-31) 23 (16-29) 0.11 23 (16-29) 22 (16-28) 19 (14-25)
Sex, male 10,184 (66) 1612 (67) 0.22 1358 (67) 249 (67) 5 (45)
HCVAb 2164 (14) 310 (13) 0.15 258 (13) 51 (14) 1 (9)
Primary disease on waiting list <0.001
Metabolic 555 (4) 57 (2) 47 (2) 10 (3) 0 (0)
Acute 1395 (9) 101 (4) 89 (4) 12 (3) 0 (0)
Cholestatic 1795 (12) 223 (9) 192 (10) 30 (8) 1 (9)
Alcoholic 3389 (22) 713 (30) 584 (29) 125 (34) 4 (36)
Malignant 2573 (17) 565 (24) 472 (23) 89 (24) 4 (36)
HBV 504 (3) 99 (4) 83 (4) 16 (4) 0 (0)
HCV 1331 (9) 185 (8) 151 (7) 33 (9) 1 (9)
Other cirrhosis 2956 (19) 378 (16) 329 (16) 48 (13) 1 (9)
Other/unknown 919 (6) 73 (3) 67 (3) 6 (2) 0 (0)
Laboratory MELD category <0.001
<15 4130 (27) 929 (39) 765 (38) 160 (43) 4 (36)
15-25 3008 (20) 680 (28) 556 (28) 120 (33) 4 (36)
26-34 1581 (10) 270 (11) 238 (12) 30 (8) 2 (18)
≥35 1504 (10) 194 (8) 175 (9) 18 (5) 1 (9)
Missing (pre-MELD era) 5194 (34) 321 (13) 280 (14) 41 (11) Not available
Match MELD category* <0.001
<15 2259 (15) 415 (17) 344 (17) 68 (18) 3 (27)
15-25 3266 (21) 707 (30) 582 (29) 120 (33) 5 (46)
26-34 3065 (20) 739 (31) 615 (31) 122 (33) 2 (18)
≥35 1633 (11) 212 (9) 193 (10) 18 (5) 1 (9)
Missing (pre-MELD era) 5194 (34) 321 (13) 280 (14) 41 (11) 0 (0)
MELD present, n 10,223 2073 1734 328 11
sRRI† 1.9 (1.6-2.3) 1.9 (1.6-2.2) 0.33 1.9 (1.6-2.2) 1.86 (1.6-2.2) 1.9 (1.6-2.2)
DRM without donor age 2.5 (2.0-3.1) 2.4 (2.0-2.8) 0.001 2.4 (2.0-2.8) 2.4 (2.1-2.8) 2.1 (2.0-3.0)
DRM with donor age 2.8 (2.3-3.5) 3.2 (2.7-3.8) <0.001 3.2 (2.8-3.8) 3.3 (2.8-3.75) 2.8 (2.6-4.1)
NOTE: Data are given as n (%) or median (IQR).
*Match MELD values are either the exceptional or laboratory MELD score used for matching.
†sRRI and DRM are calculated for all recipients after MELD implementation in December 2006.
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donor age of 25 years, after which the risk increases 
linearly up to 80 years old. As of a donor age of 80 
years, the risk seems to increase even further, although 
the 95% CI increases because of limited numbers.
OUtcOMe in preFerred and 
nOnpreFerred recipients
Transplantations were then divided into 2 groups of 
preferred and nonpreferred recipients as described by 
Segev et al.(11) (Fig. 4). According to these criteria (re-
cipient age >45 years old, recipient BMI <35 kg/m2, 
etiology of liver diseases other than HCV cirrhosis, and 
CIT <8 hours), 4576 (26%) and 13,235 (74%) patients 
were identified as preferred and nonpreferred recipi-
ents, respectively. A similar distribution of laboratory 
MELD score was present in both groups (Supporting 
Fig. 2).
In preferred recipients, there was only a minor, 
nonstatistically significant difference in graft survival 
between recipients who underwent transplantation 
with a liver younger than 70 or older than 70 years 
old (HR, 1.1; 95% CI, 0.92-1.23; P = 0.40; Fig. 4A). 
In nonpreferred recipients on the contrary, a donor 
age over 70 years old had a significant impact on graft 
survival (HR, 1.2; 95% CI, 1.14-1.35; P < 0.001; 
Fig. 4B). An even more distinctive difference between 
preferred and nonpreferred recipients was observed 
when comparing transplantations with a donor below 
40 years old or of 70 years old and older. In preferred 
recipients, no statistically significant difference could 
be observed in graft survival at 5 years (HR, 1.2; 95% 
CI, 0.96-1.37; P = 0.13; Fig. 4C), whereas it had a 
major impact in nonpreferred recipients (HR, 1.5; 95% 
CI, 1.39-1.71; P < 0.001; Fig. 4). Similar results were 
observed for patient survival at 5 years (Supporting 
Fig. 3A-D).
center analYsis
No difference in outcome of transplantations with liv-
ers ≥70 years old (n = 2394) was observed when centers 
were stratified according to the number of transplanted 
with livers ≥70 years old (≤70 or >70 transplanta-
tions; P = 0.781) or by proportion of livers >70 years 
old (≤12% or >12%; P = 0.395; Supporting Fig. 4A,B) 
in the study period. High proportion centers tended to 
transplant younger donors (54 years old versus 49 years 
old; P < 0.001), but no (clinical) significant differences 
Fig. 3. The adjusted risk of donor age on graft survival (n = 
12,296). Donor age has a linear, increasing risk for graft survival 
from 25 years old up to 80 years old, that shows no signs of 
decreasing over 80 years old.
0 20 40 60 80 100
−
0.
6
−
0.
4
−
0.
2
0.
0
0.
2
0.
4
0.
6
0.
8
Donor age (years)
Pa
rti
al
 fo
r 
ps
pl
in
e 
(do
no
r a
ge
,
 
df
 =
 4
)
taBle 5. Multivariate analysis of Factors associated With 
10-Year graft survival of transplantations With livers ≥70 
Years Old With a Known Meld score (n = 2073)
Wald HR 95% CI p–Value
Donor
Age, years 1.02 1.003-1.036 0.02
Medical history,
DM (yes) 1.30 1.047-1.500 0.01
Transplant
Cold ischemia time 
(continuos hours)
1.04 1.019-1.071 0.001
Rescue_R (yes) 1.21 1.036-1.422 0.02
Recipient
Age (>45 years old) 0.74 0.586-0.923 0.01
Sex, male 1.19 1.020-1.386 0.03
LabMELD 
(categorial)
47,366 <0.001
<15 Reference Reference
≥15 and <25 1.1 0.905-1.261 0.44
≥25 and <35 1.5 1.206-1.887 <0.001
≥35 2.2 1.747-2.826 <0.001
HCVAb (positive) 1.5 1.229-1.801 <0.001
NOTE: Not significant in multivariate analysis backward selec-
tion (Wald): donor sex, donor type, split liver, hypotensive period, 
allocation region, BMI, cause of death, last ALAT, ASAT, biliru-
bin, HBcAb, HCVAb, cardiac arrest, recipient BMI, and etiology 
of disease.
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in median laboratory MELD score (17 versus 16; 
P < 0.001) or CIT (8.8 hours versus 8.9 hours; P = 0.96) 
were observed as compared with low proportion centers.
When centers were categorized according to out-
come of transplantations with livers ≥70 years old, 
6 centers (n = 570 LTs) had significantly “better 
than expected” graft survival at 5-year follow-up, 
whereas 8 (n = 649 LTs) and 20 transplantation cen-
ters (n = 1160 LTs), respectively, had “worse than 
expected” or “as expected” outcome (Supporting 
Fig. 4. Graft survival in preferred recipients versus nonpreferred recipients. (A) In preferred recipients, no statistical significant 
difference can be observed in graft survival whether transplanted with a liver below or over 70 years old (HR 1.1; CI 0.92-1.23, 
P = 0.40). In nonpreferred recipients, this difference in outcome is statistically significant (B) whether transplanted with a liver below 
or over 70 years old (HR 1.2; CI 1.14-1.35, P < 0.001). Also, significant differences can be detected when comparing transplantations 
with livers below 40 years old or of 70 years and older. In preferred recipients (C) no difference was observed (HR 1.2; CI 0.96-1.37, 
P = 0.13) while a statistically significant  difference was observed in nonpreferred recipients (D) (HR 1.5; CI 1.39-1.71, P < 0.001).
0 1 2 3 4 5
0
20
40
60
80
10
0
Time (years)
Su
rv
iva
l (%
)
Graft survival, preferred
0 1 2 3 4 5
0
20
40
60
80
10
0
Time (years)
Su
rv
iva
l (%
)
Graft survival, nonpreferred
0 1 2 3 4 5
0
20
40
60
80
10
0
Time (years)
Su
rv
iva
l (%
)
Graft survival, preferred
0 1 2 3 4 5
0
20
40
60
80
10
0
Time (years)
Su
rv
iva
l (%
)
Graft survival, nonpreferred
(a) (b)
(c) (d)
de BOer et al. liver transplantatiOn,  February 2019
270 | Original article
Fig. 4C). Characteristics of these groups are shown in 
Supporting Table 2. Most notably, centers with better 
than expected performance transplanted these livers 
≥70 years old more often in preferred recipients and 
transplanted more locally procured livers.
UtiliZatiOn OF repOrted 
livers
Out of all reported livers of ≥70 years, 1022 out of 3416 
(30%) livers were not transplanted. Characteristics of 
transplanted versus nontransplanted liver allografts are 
shown in Supporting Table 1. Most notably, hepatitis 
B virus (HBV) and HCV were more often observed 
in nontransplanted livers with rates for HBV of 12% 
versus 8% (P ≤ 0.001), and HCV of 3% versus 0% 
(P ≤ 0.001), respectively. Also, diabetes was more 
often present in donors of nontransplanted livers 
(23% versus 16%; P ≤ 0.001), and laboratory values 
(GGT, transaminases, and bilirubin) were signifi-
cantly higher in donors of nontransplanted livers. The 
utilization rate increased from 42% in 2000-2003 to 
77% in 2010-2012 and stabilized at 76% in 2013-2015 
(Fig. 5). Of all 1022 nontransplanted livers, 374 (37%) 
were procured. The proportion of nontransplanted liv-
ers that were procured increased from 23% (35/151) in 
2000-2003 to 41% (89/216) in 2013-2015. Reasons for 
discarding the liver allografts (n = 416) were reported 
in 82% of all procured livers and mostly concerned 
organ quality. Steatosis was most often mentioned as 
the reason for discarding the organ (36%), followed 
by fibrosis (14%) and a (suspected) malignancy in the 
donor (14%). All other reasons are shown in Table 6.
Discussion
This study shows that an important and increas-
ing proportion of LTs in ET is performed with liv-
ers from donors of ≥70 years. These donors are not 
only more often reported in recent years but are also 
increasingly more efficiently used for transplantation. 
We have shown that an increasing donor age is linearly 
associated with graft loss between 25 years old up to 
80 years old, without evidence of decreasing after 80 
years. Additional risk factors like a history of diabetes 
in the donor and HCV in the recipient should there-
fore be avoided when transplanting older livers. With 
an adequate selection, wait-list mortality can be safely 
further reduced by increasing the number of reported 
liver allografts from donors of ≥70 years for preferred 
recipients.
The high shortage of transplantable liver allografts 
has led to an international expansion of acceptable donor 
criteria. Within ET, the extent of aging of transplanted 
livers is distinctive; the median donor age increased 
Fig. 5. Utilization of livers ≥70 years old. Number of livers ≥70 years old reported to ET by transplantation status (numbers). Number 
of livers ≥70 years old reported to ET by transplantation status (relative %).
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from 43 to 55 years in only 15 years. Currently, over 
10% of all transplantations in adult recipients in ET 
are performed with livers of ≥70 years. Results from 
this study show that outcomes could potentially be 
improved by optimizing our patient selection. This is 
an important issue because of the expected increase in 
transplanted livers from donors of advanced age. The 
increase will be likely caused by a higher availability 
and because these organs will be more readily accepted. 
The increased availability is because Western popula-
tions are aging rapidly, and the higher acceptance rate 
is likely because of the persisting shortage that was also 
observed in this study (Fig. 5; from 42% to 76%).
With this development, defining the effect of an 
increasing donor age on outcome becomes more and 
more important. Considering the oldest transplanted 
liver in our study was 98 years old, the question arises 
as to whether there is a maximum donor age at all. In 
this study, we have shown that the risk of graft loss 
increases linearly from a donor age of 25 up to 80 years 
old. The risk of livers from donors of 80 years may 
increase nonlinearly and suggests that these organs 
reach the outer limits of biological flexibility despite 
their regenerative capacity.(14,15)
risK FactOrs
To balance the risk of an increased donor age, other 
risk factors should be avoided or adjusted. We identi-
fied a history of diabetes, prolonged CIT, rescue al-
location, male sex, MELD score category, and HCV 
positive in the recipient as risk factors for decreased 
outcome of LT with older livers. This is in line with 
the factors that were identified by Ghinolfi et al. 
including a history of diabetes.(8) Diabetes is more 
often present in older donors and may have a stron-
ger and more chronic effect on the vasculature and 
parenchyma in older donor livers.(8,16,17) Diabetes, 
therefore, seems to be an important risk factor that 
should be avoided when possible. Another risk fac-
tor with a potential higher inf luence on older livers 
is prolonged CIT.(18) Considering the recipient se-
lection criteria that were used by Segev et al.,(11) we 
could confirm CIT, HCV, and a recipient age <45 
years, but not recipient BMI (continuous or with a 
BMI of 35 kg/m2 as a cutoff). Yet, we have confirmed 
their findings that in “preferred patients” donor age 
has no significant effect as compared with “nonpre-
ferred recipients.”
liMitatiOns
When evaluating patient selection criteria, analyses 
are likely to confirm “classical” selection patterns for 
older donors. These livers are generally accepted for 
older recipients(7,8,19-21) with lower laboratory MELD 
scores(22,23) who more often suffer from malignant dis-
ease.(7,20,21) This previously observed selection bias is 
inherent to the retrospective design and was also ob-
served in this study: livers of donors of 70 years and 
older had shorter ischemia times, had diabetes less 
often, and underwent transplantation in recipients 
with lower laboratory MELD scores. We have there-
fore adjusted outcomes for significant risk factors to 
better assess the effect of an increasing donor age. 
In adjusting for risk factors, we considered GGT as 
a proxy for steatosis(24) because information on biop-
sies was insufficiently available. We considered graft 
survival a primary outcome because information on 
biliary complications or early bile production was not 
available in the ET database. This is a potential lim-
itation because some studies found suggestions for 
more biliary complications in transplantations with 
livers from elderly donors.(3,17,25-27) However, biliary 
taBle 6. reasons for discarding Older livers
Value (n = 374)
Organ quality
Steatosis 135 (36)
Fibrosis 52 (14)
Cirrhosis 19 (5)
Vascular/perfusion 24 (6)
Infection 8 (2)
Other* 63 (17)
Donor quality
(Suspected) malignancy 52 (14)
Virology (HBV/HCV) 8 (2)
Other† 16 (4)
Other reasons
(Expected) CIT 24 (6)
Other‡ 4 (1)
No information available 69 (18)
*Includes organ not transplantable for unspecified quality rea-
sons, histology, macroscopy, transaminases, cholelithiasis, injury, 
and anatomical issues.
†Includes reanimation or age.
‡Includes no recipients because of blood group (AB) or because 
patient was not transplantable.
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complications will likely also affect graft survival in 
the long run.
OUtcOMes in OtHer stUdies
The presented results of outcomes after transplanta-
tion with a liver from an older donor are in  accordance 
with results from other regions, although these are 
reported with a high variance. Reported patient sur-
vival rates at 1 year vary from 70% to 90%(7,9,28-33) 
and 5-year patient survival rates from 50% to 
80%.(7,20,28-30,34) The sometimes very promising 
outcomes(7-9,31,32) are apparently contradicting to 
the higher intrinsic risk of older donors.(10,35) These 
results are therefore likely to be explained by the fre-
quent single-center design, relatively small numbers 
of included transplantations, different aging patterns 
in other countries,(36) and differences in recipient and 
donor selection criteria. The latter is present in our 
study and also observed in these other studies. Older 
liver allografts have shorter CITs,(7-9,20,23,27,29) more 
often have pretransplant biopsies,(8,16,20,22,29,37) have 
a lower incidence of cardiac arrest,(7,8,20-23,27) and are 
more frequently regionally procured.(8,22,23) All of 
these are obviously meant to decrease the initial risk 
of the geriatric liver allograft.
UtiliZatiOn in OtHer stUdies
Utilization rates for donors aged ≥70 years old in-
creased in our study from 42% (2000-2003) to 77% 
(2010-2012) and remained at 76% between 2013 and 
2015. In the overall study period, the utilization rate 
was 70% for livers ≥70 years old and 69% for livers 
≥80 years. The utilization rate of livers ≥70 years 
old was even slightly higher at 72% when livers that 
were used for retransplantations were included (data 
not shown). These rates are very high in comparison 
to other studies who report usage rates of approx-
imately 60%(38) and 52%-63% for liver donors ≥70 
years and ≥80 years old, respectively.(7,16,38) It does, 
however, correspond with usage in the United States 
where 74% of livers of 70 years and older are used for 
transplantation.(10) Although the United States has 
a similar utilization rate, it is of note that the pro-
portion of transplantations with donors ≥70 years of 
all performed transplantations is much higher within 
ET as compared with the United States. By using the 
same inclusion criteria as Halazun et al.,(10) in ET 
2625 out of 21,644 (12%) transplantations in adults 
were performed with donors from 70 years and older 
as compared with 4.3% in the United States (data 
from ET).
iMplicatiOns
Outcomes of geriatric LT in ET can likely be further 
improved based on the center-specific analysis. Centers 
with better than expected outcomes transplanted the 
livers ≥70 years old more often in preferred recipients 
and less often in recipients with HCV. In addition, 
these centers accepted more often locally procured or-
gans and transplanted livers with relatively short isch-
emic times. These potentially beneficial factors can be 
further supported by modifying allocation algorithms 
to decrease CITs and to improve our patient selection. 
For example, CITs could be further reduced by more 
regional allocation or even by allocation to the donor 
hospital. This could positively affect outcomes and 
might even prevent organ loss. Approximately 6% of 
procured and not transplanted livers in this study were 
also declined due to long CITs. Another option would 
be to improve our donor-recipient matching because 
we have confirmed good outcomes of older livers in 
preferred recipients as defined by Segev et al.(11) It is 
interesting that posttransplantation outcomes in these 
preferred recipients are not significantly affected by 
older donor age. Although not fully understood, the 
factors recipient age >45 years, BMI <35 kg/m2, and 
CIT <8 hours seem to be effective variables for recip-
ient selection and do also apply to a European popula-
tion of liver patients.
Besides improving outcomes of currently used older 
livers, we have to focus on improving the use of cur-
rently reported livers and to increase the number of 
reported livers itself. The relative use can potentially 
increase based on the reasons for discarding organs. 
Several factors, like CIT, might be resolved or atten-
uated with the use of machine perfusion. It would at 
least enable us to better assess the actual quality or func-
tion of the graft prior to the transplantation to safely 
transplant livers that are now discarded.(39) Second, we 
should strive to improve the number of older donors 
who are reported. The willingness of centers to accept 
and transplant these older organs is very high. The 
maximum donor age that doctors will consider for spe-
cific patients increased from 75 to 87 years between 
September 2003 and December 2015 based on the 
individual acceptance criteria of patients entered in 
the ET liver allocation system. On a center level, the 
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maximum donor age is currently even set at 100 years 
old for 15 out of 38 (40%) LT centers (data ET). It 
might be true that acceptance criteria have expanded 
faster than criteria for reporting donors. Because there 
were only relatively small differences in baseline char-
acteristics between transplanted and nontransplanted 
livers, we suggest avoiding an age limit to report poten-
tial donors. Because of this, otherwise transplantable 
older donor livers will not be missed.
In conclusion, liver allografts from donors aged 70 
years or older are more often and more efficiently used 
for LT in the ET region. These advanced age donors 
provide an important additional number of livers avail-
able for transplantation. Donor age is an independent 
risk factor with a linear relation with inferior graft sur-
vival from 25 up to 80 years old. Yet, transplantations 
performed with livers from donors of an advanced age 
can lead to similar outcomes in preferred recipients. 
Older donors should therefore be reported less cau-
tiously and allocated to preferred recipients to further 
decrease wait-list mortality safely.
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